Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Antineoplastic Agents

All Drugs and Chemicals

Daratumumab

Ciforadenant 100 mg orally twice daily in combination with daratumumab IV 16 mg/kg.

100 mg orally twice daily for 28-day cycles

Ciforadenant

16 mg/kg administered intravenously as follows based on 28-day cycles:

* Cycles 1 - 2: Days 1, 8, 15, and 22
* Cycles 3 - 6: Days 1 and 15
* Cycles 7 - 24: Day 1

daratumumab

Deborah Strahs

This is a Phase 1b open-label study of ciforadenant, an oral, small molecule inhibitor targeting adenosine-2A receptors (A2AR), on safety/tolerability and efficacy in combination with daratumumab, a monoclonal antibody targeting CD38, in relapsed or refractory multiple myeloma.

Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

An Open-Label Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

Incidence of treatment-emergent adverse events, as assessed by NCI CTCAE v.5

Incidence of dose-limiting toxicities (DLTs) of CPI-444 in combination with daratumumab

According to international myeloma working group guidelines (including stringent complete response \[sCR\], complete response \[CR\], very good partial response \[VGPR\], partial response \[PR\]).

Time from the first assessment showing objective response to the date of documented disease progression.

Proportion of participants achieving disease control for ≥ 3 months.

Time from end of treatment to starting next anti-myeloma therapy.

Proportion of participants remaining progression free or surviving at a given time.

Rate of molecular minimal residual disease (MRD) negativity.

Corvus Pharmaceuticals, Inc.

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Prostatic Neoplasms

Carcinoma, Renal Cell

Kidney Neoplasms

Carcinoma

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Urologic Neoplasms

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Renal Cell Carcinoma

Atezolizumab

Immune Checkpoint Inhibitors

Antineoplastic Agents, Immunological

100 mg orally twice daily for the first 14 days of each 28-day cycle.

100 mg orally twice daily for 28 days of each 28-day cycle.

200 mg orally once daily for the first 14 days of each 28-day cycle.

Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.

Ciforadenant + atezolizumab

Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.

Mehrdad Mobasher, MD, MPH

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, an intravenous PD-L1 inhibitor. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Genentech, Inc.

Clear Cell Renal Cell Carcinoma

Anti-Arrhythmia Agents

Vasodilator Agents

Analgesics

Nivolumab

Ipilimumab

Adenosine

To help control advanced renal cell carcinoma.

Eric Jonasch, MD

Daniel George, MD

To learn if the combination of ciforadenant, ipilimumab, and nivolumab can help to control advanced renal cell carcinoma

Primary Objectives:

* To determine the safety and tolerability of ipilimumab, nivolumab, and ciforadenant in patients with untreated advanced renal cell carcinoma (RCC).
* To assess the depth of responsein patients with untreated advanced renal cell carcinoma treated with ipilimumab, nivolumab, and ciforadenant.

Secondary Objectives:

• To estimate the objective response rate (ORR), duration of response (DOR) progression free survival (PFS), progressive disease (PD) rate, and irAE rate of ipilimumab, niovlumab, and Ciforadenant combination in untreated advanced RCC.

Exploratory Objectives:

• To assess association of gene expression signatures and pharmacodynamic parameters with outcome.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma	NCT04280328	Multiple Myelom...	Ciforadenant daratumumab	18 Years - 80 Years	Corvus Pharmaceuticals, Inc.
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	NCT02655822	Renal Cell Canc... Metastatic Cast...	Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant	18 Years -	Corvus Pharmaceuticals, Inc.
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	NCT02655822	Renal Cell Canc... Metastatic Cast...	Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant	18 Years -	Corvus Pharmaceuticals, Inc.
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.	NCT05501054	Renal Cell Carc...	Ipilimumab Nivolumab Ciforadenant	18 Years -	M.D. Anderson Cancer Center
Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers	NCT02655822	Renal Cell Canc... Metastatic Cast...	Ciforadenant Ciforadenant Ciforadenant Ciforadenant + ... Ciforadenant	18 Years -	Corvus Pharmaceuticals, Inc.
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.	NCT05501054	Renal Cell Carc...	Ipilimumab Nivolumab Ciforadenant	18 Years -	M.D. Anderson Cancer Center
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma	NCT04280328	Multiple Myelom...	Ciforadenant daratumumab	18 Years - 80 Years	Corvus Pharmaceuticals, Inc.

Spots Global Cancer Trial Database for ciforadenant

Every month we try and update this database with for ciforadenant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.